• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novo Nordisk promotes four to senior vice president

Novo Nordisk promotes four to senior vice president

February 1, 2013
CenterWatch Staff

Novo Nordisk, a global healthcare company, has promoted four corporate vice presidents to senior vice presidents. Effective March 1, 2013, the following members of the U.S. executive team will assume the title of senior vice president in their respective areas: Andy Ajello, U.S. national diabetes sales; Camille Lee, U.S. diabetes marketing; Alan Moses, MD, global chief medical officer; and Anne Phillips, MD, U.S. clinical, medical and regulatory affairs.

Ajello has been in the pharmaceutical industry for nearly 20 years. He joined Novo Nordisk in March 2001 and currently leads the national diabetes sales strategy and the company's approximately 3,200 person field sales organization. During Ajello’s 12 years with the company, he has been widely recognized for developing and motivating a high-performing sales team. His responsibilities include oversight of the entire diabetes sales organization, including managed markets sales, field force operations and strategic sales initiatives.

Lee has more than 25 years of experience in the industry. She joined Novo Nordisk in 1985 as a sales representative in Southern California, and through her tenure with the company has held national and international positions of increasing authority in the areas of marketing, strategic launch planning and sales management. Over the past six years, Lee has built a strong diabetes marketing team of 365 people that has been recognized internally and externally for their best-in-class initiatives. She currently has oversight for the marketing of all in-line and future brands, as well as the organization's diabetes educator program.

Moses joined Novo Nordisk in 2004 from Harvard Medical School and the Joslin Diabetes Center as associate vice president for clinical research and medical affairs, endocrinology, and in 2007 was named chief medical officer for North America. One year later, he was appointed to global chief medical officer. Moses is involved in the full spectrum of Novo Nordisk's diverse diabetes work from drug discovery to addressing the implications of diabetes for patients, healthcare professionals and healthcare systems.

Phillips brings more than 20 years of medical, research and regulatory experience to her role. She currently leads an integrated drug development, medical, regulatory and safety team of more than 550 people, and plays a key role in advancing Novo Nordisk's diabetes and biopharmaceutical clinical development pipelines. Phillips is responsible for the efficient development and delivery of compounds in clinical trials, including product lifestyle and in-licensed compounds.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing